Drug Approval | August 03, 2021
AYUSH 64 effective in mild and moderate COVID 19
It works as an adjunct to standard care based on robust clinical trials
It works as an adjunct to standard care based on robust clinical trials
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Turnover of API division of ISLL stood at Rs 856.58 crore
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
Price band in the range of Rs 933 to Rs 954
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
Earlier, the USFDA has granted ‘Orphan Drug Designation’ and ‘Fast Track Designation’ to Saroglitazar Mg for PBC
Subscribe To Our Newsletter & Stay Updated
